Terms: = Leukemia AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1
361 results:
1. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract] [Full Text] [Related]
2. Increased Anti-Inflammatory Therapeutic Potential and Progenitor Marker Expression of Corneal Mesenchymal Stem Cells Cultured in an Optimized Propagation Medium.
Hopkinson A; Notara M; Cursiefen C; Sidney LE
Cell Transplant; 2024; 33():9636897241241992. PubMed ID: 38602231
[TBL] [Abstract] [Full Text] [Related]
3. Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis.
Xu K; Zhuang XX; Shi XW
Expert Rev Hematol; 2024; 17(1-3):87-94. PubMed ID: 38230679
[TBL] [Abstract] [Full Text] [Related]
4. ABC transporters are predictors of treatment failure in acute myeloid leukaemia.
Cerovska E; Salek C; Kundrat D; Sestakova S; Pesek A; Brozinova I; Belickova M; Remesova H
Biomed Pharmacother; 2024 Jan; 170():115930. PubMed ID: 38039756
[TBL] [Abstract] [Full Text] [Related]
5. Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Switchenko JM; Costanza E; Uricoli B; Wang X; Jui NT; Fu H; Du Y; DeRyckere D; Graham DK; Dreaden EC
Pharm Res; 2023 Sep; 40(9):2133-2146. PubMed ID: 37704893
[TBL] [Abstract] [Full Text] [Related]
6. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
He S; Shao Q; Zhao J; Bian J; Zhao Y; Hao X; Li Y; Hu L; Liu B; He H; Huang L; Jiang Q
Cancer Chemother Pharmacol; 2023 Nov; 92(5):399-410. PubMed ID: 37624393
[TBL] [Abstract] [Full Text] [Related]
7. Modes of Action of a Novel c-MYC Inhibiting 1,2,4-Oxadiazole Derivative in leukemia and Breast Cancer Cells.
Zhou M; Boulos JC; Omer EA; Klauck SM; Efferth T
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570631
[TBL] [Abstract] [Full Text] [Related]
8. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM; Chimenti ML; Zhang DY; Williams EK; Moore SG; Humber GM; Baxter TA; Birnbaum LA; Qui M; Zecca H; Thapa A; Jain J; Jui NT; Wang X; Fu H; Du Y; Kemp ML; Lam WA; Graham DK; DeRyckere D; Dreaden EC
J Control Release; 2023 Sep; 361():470-482. PubMed ID: 37543290
[TBL] [Abstract] [Full Text] [Related]
9. The cardiac glycoside ZINC253504760 induces parthanatos-type cell death and G2/M arrest via downregulation of MEK1/2 phosphorylation in leukemia cells.
Zhou M; Boulos JC; Klauck SM; Efferth T
Cell Biol Toxicol; 2023 Dec; 39(6):2971-2997. PubMed ID: 37322258
[TBL] [Abstract] [Full Text] [Related]
10. abcg2 in Acute Myeloid leukemia: Old and New Perspectives.
Damiani D; Tiribelli M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108308
[TBL] [Abstract] [Full Text] [Related]
11. Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid leukemia Cell Lines.
Kutyna MM; Loone S; Saunders VA; White DL; Kok CH; Hiwase DK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834962
[TBL] [Abstract] [Full Text] [Related]
12. Impact of
Dalle Fratte C; Polesel J; Gagno S; Posocco B; De Mattia E; Roncato R; Orleni M; Puglisi F; Guardascione M; Buonadonna A; Toffoli G; Cecchin E
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834713
[TBL] [Abstract] [Full Text] [Related]
13. Cytotoxicity of the methanol extracts and compounds of Brucea antidysenterica (Simaroubaceae) towards multifactorial drug-resistant human cancer cell lines.
Youmbi LM; Makong YSD; Mbaveng AT; Tankeo SB; Fotso GW; Ndjakou BL; Wansi JD; Beng VP; Sewald N; Ngadjui BT; Efferth T; Kuete V
BMC Complement Med Ther; 2023 Feb; 23(1):48. PubMed ID: 36793009
[TBL] [Abstract] [Full Text] [Related]
14. Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
Solana-Altabella A; Megías-Vericat JE; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
Expert Rev Clin Pharmacol; 2023 Feb; 16(2):133-148. PubMed ID: 36708283
[TBL] [Abstract] [Full Text] [Related]
15. Association of ABCB1, abcg2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
[TBL] [Abstract] [Full Text] [Related]
16. Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer.
Yan B; Shi R; Lu YY; Fang DD; Ye MN; Zhou QM
PLoS One; 2023; 18(1):e0279752. PubMed ID: 36693064
[TBL] [Abstract] [Full Text] [Related]
17. A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of abcg2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid leukemia Patients.
Sabri A; Omran MM; Azim SA; Abdelfattah R; Allam RM; Shouman SA
Drug Res (Stuttg); 2023 Mar; 73(3):146-155. PubMed ID: 36630991
[TBL] [Abstract] [Full Text] [Related]
18. Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients.
Fukushi Y; Akamine Y; Abumiya M; Tozawa N; Yamashita T; Nara M; Kameoka Y; Takahashi N; Miura M
Br J Clin Pharmacol; 2023 May; 89(5):1695-1700. PubMed ID: 36541130
[TBL] [Abstract] [Full Text] [Related]
19. Effects of splicing-regulatory polymorphisms in ABCC2, abcg2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
Li M; Kong XY; Wang SM
Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
[TBL] [Abstract] [Full Text] [Related]
20. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or abcg2.
Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
[TBL] [Abstract] [Full Text] [Related]
[Next]
